Your browser doesn't support javascript.
loading
Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis.
Insua-Rodríguez, Jacob; Pein, Maren; Hongu, Tsunaki; Meier, Jasmin; Descot, Arnaud; Lowy, Camille M; De Braekeleer, Etienne; Sinn, Hans-Peter; Spaich, Saskia; Sütterlin, Marc; Schneeweiss, Andreas; Oskarsson, Thordur.
Afiliação
  • Insua-Rodríguez J; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
  • Pein M; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hongu T; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
  • Meier J; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
  • Descot A; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lowy CM; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
  • De Braekeleer E; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
  • Sinn HP; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Spaich S; Department of Physiological Chemistry and Department of Environmental Biology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Sütterlin M; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
  • Schneeweiss A; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Oskarsson T; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
EMBO Mol Med ; 10(10)2018 10.
Article em En | MEDLINE | ID: mdl-30190333
ABSTRACT
Metastatic progression remains a major burden for cancer patients and is associated with eventual resistance to prevailing therapies such as chemotherapy. Here, we reveal how chemotherapy induces an extracellular matrix (ECM), wound healing, and stem cell network in cancer cells via the c-Jun N-terminal kinase (JNK) pathway, leading to reduced therapeutic efficacy. We find that elevated JNK activity in cancer cells is linked to poor clinical outcome in breast cancer patients and is critical for tumor initiation and metastasis in xenograft mouse models of breast cancer. We show that JNK signaling enhances expression of the ECM and stem cell niche components osteopontin, also called secreted phosphoprotein 1 (SPP1), and tenascin C (TNC), that promote lung metastasis. We demonstrate that both SPP1 and TNC are direct targets of the c-Jun transcription factor. Exposure to multiple chemotherapies further exploits this JNK-mediated axis to confer treatment resistance. Importantly, JNK inhibition or disruption of SPP1 or TNC expression sensitizes experimental mammary tumors and metastases to chemotherapy, thus providing insights to consider for future treatment strategies against metastatic breast cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Transdução de Sinais / Resistencia a Medicamentos Antineoplásicos / Metástase Neoplásica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Transdução de Sinais / Resistencia a Medicamentos Antineoplásicos / Metástase Neoplásica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article